

CHAPTER 12 — REFERENCES

1. American Cancer Society Board of Directors. ACS Challenge goals for U.S. Cancer Mortality for the Year 2015. *Proceedings of the Board of Directors*. Atlanta, GA: American Cancer Society, 1996.
2. American Cancer Society Board of Directors. ACS Challenge goals for U.S. Cancer Incidence for the Year 2015. *Proceedings of the Board of Directors*. Atlanta, GA: American Cancer Society, 1998.
3. Centers for Disease Control and Prevention. National Program of Cancer Registries (NPCR) Web site. <http://cdc.gov/cancer/npcr>.
4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program Web site. <http://seer.cancer.gov>.
5. Centers for Disease Control and Prevention. U.S. mortality data. <http://wonder.cdc.gov/ucd-icd10.html>
6. Jemal A, Simard E, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. *J Natl Cancer Inst* 2013;105:175–201.
7. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Web site. <http://cdc.gov/brfss>.
8. Ward E, Thun M, Hannan L, et al. Interpreting cancer trends. *Ann NY Acad Sci* 2006;1076:29–53.
9. Centers for Disease Control and Prevention. Smoking & Tobacco Use Web site. <http://cdc.gov/tobacco>.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321–333.
11. Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. *JAMA* 2004;291:47–53.
12. Ryerson AB, Miller J, Ehemam CR, et al. Use of mammograms among women aged ≥ 40 years—United States, 2000–2005. *MMWR* 2007;56:49–51.
13. Giovino GA. Epidemiology of tobacco use in the United States. *Oncogene* 2002;21:7326–7340.
14. Oken M, Hocking W, Kvale P, et al. Screening by chest radiograph and lung cancer mortality. *JAMA* 2011;306:1865–1873.
15. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
16. Smith R, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. *CA Cancer J Clin* 2013;63:88–105.
17. U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Web site. <http://uspreventiveservicestaskforce.org>.
18. Martinez ME. Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. *Recent Results Cancer Res* 2005;166:177–211.
19. Atkin W, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomized controlled trial. *Lancet* 2010;375:1624–1633.
20. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med* 2012;366:2345–2357.
21. Cram P, Fendrick A, Inadomi J, et al. The impact of celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. *Arch Intern Med* 2003;163(13):1601–1605.
22. World Cancer Research Fund/American Institute for Cancer Prevention. *Policy and Action for Cancer Prevention. Food, Nutrition, and Physical Activity: A Global Perspective*. Washington, DC: AICR; 2009.
23. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. *JAMA* 2006;295:1549–1555.
24. Vogel V, Constantino J, Wickerham D, et al. Effects of tamoxifen vs raloxifene on the risks of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727–2741.
25. Berry D, Cronin K, Plevritis S, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med* 2005;353:1784–1792.
26. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360(13):1310–1319.
27. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360(13):1320–1328.
28. Andriole G, Crawford D, Grubb R, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst* 2012;104:125–132.
29. Thompson I, Goodman P, Tangen C, et al. Long-term survival of participants in the prostate cancer prevention trial. *N Engl J Med* 2013;369:603–610.
30. International Agency for Cancer Research. *Weight Control and Physical Activity. Handbook 6*. Lyon, France: IARC Press; 2002.
31. Sedjo R, Byers T, Barrera E, et al. A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015. *CA Cancer J Clin* 2007;57:326–340.
32. Byers T, Barrera E, Fontham E, et al. A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. *Cancer* 2006;107:396–405.
33. Byers T, Mouchawar J, Marks J, et al. The American Cancer Society challenge goals. How far can cancer rates decline in the U.S. by the year 2015? *Cancer* 1999;86:715–727.